PMID- 16584914
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20110714
LR  - 20200929
IS  - 1386-6346 (Print)
IS  - 1386-6346 (Linking)
VI  - 35
IP  - 2
DP  - 2006 Jun
TI  - 2-Mercaptoethane sulfonate (MESNA) protects against biliary obstruction-induced 
      oxidative damage in rats.
PG  - 140-6
AB  - The aim of this study was to assess the antioxidant and antifibrotic effects of 
      chronic administration of 2-mercaptoethane sulfonate (MESNA) on oxidative liver 
      damage and fibrosis induced by biliary obstruction in rats. Liver fibrosis was 
      induced in male Wistar albino rats by bile duct ligation and scission (BDL). 
      MESNA (150mg/kg, i.p.) or saline was administered for 28 days. At the end of the 
      experiment, rats were killed by decapitation. Serum aspartate aminotransferase 
      (AST), and alanine aminotransferase (ALT) levels were determined to assess liver 
      function. Tumor necrosis factor-alpha (TNF-alpha) and lactate dehidrogenase (LDH) 
      were also assayed in serum samples. Liver tissues were taken for determination of 
      the free radicals, hepatic malondialdehyde (MDA) levels, an end product of lipid 
      peroxidation; glutathione (GSH) levels, a key antioxidant; myeloperoxidase (MPO) 
      activity, as an indirect index of neutrophil infiltration. Hepatic collagen 
      content, as a fibrosis marker was also determined. Serum AST, ALT, LDH and 
      TNF-alpha levels were elevated in the BDL group as compared to control group, 
      while this increase was significantly decreased by MESNA treatment. BDL caused a 
      significant (p<0.05-0.001) decrease in GSH levels while MDA levels and MPO 
      activity were increased in the liver tissue. These changes were reversed by MESNA 
      treatment. Collagen contents of the liver tissue was increased by BDL (p<0.001), 
      and reversed back to the control levels with MESNA. Since MESNA administration 
      alleviated the BDL-induced oxidative injury of the liver and improved the hepatic 
      functions, it seems likely that MESNA with its antioxidant and antifibrotic 
      properties, may be of potential therapeutic value in protecting the liver 
      fibrosis and oxidative injury due to biliary obstruction.
FAU - Sener, Goksel
AU  - Sener G
AD  - Marmara University, School of Pharmacy, Department of Pharmacology, Istanbul, 
      Turkey.
FAU - Kabasakal, Levent
AU  - Kabasakal L
FAU - Sehirli, Ozer
AU  - Sehirli O
FAU - Ercan, Feriha
AU  - Ercan F
FAU - Gedik, Nursal
AU  - Gedik N
LA  - eng
PT  - Journal Article
DEP - 20060403
PL  - Netherlands
TA  - Hepatol Res
JT  - Hepatology research : the official journal of the Japan Society of Hepatology
JID - 9711801
EDAT- 2006/04/06 09:00
MHDA- 2006/04/06 09:01
CRDT- 2006/04/06 09:00
PHST- 2005/12/01 00:00 [received]
PHST- 2006/02/22 00:00 [revised]
PHST- 2006/02/24 00:00 [accepted]
PHST- 2006/04/06 09:00 [pubmed]
PHST- 2006/04/06 09:01 [medline]
PHST- 2006/04/06 09:00 [entrez]
AID - S1386-6346(06)00077-5 [pii]
AID - 10.1016/j.hepres.2006.02.009 [doi]
PST - ppublish
SO  - Hepatol Res. 2006 Jun;35(2):140-6. doi: 10.1016/j.hepres.2006.02.009. Epub 2006 
      Apr 3.